Financial Performance - For the six months ended September 30, 2024, the company reported revenue of HKD 37,186,000, a decrease of 55.5% compared to HKD 83,427,000 in the same period of 2023[2] - The gross profit for the same period was HKD 1,009,000, down from HKD 12,022,000, indicating a significant decline in profitability[2] - The company incurred an operating loss of HKD 1,553,000, compared to an operating profit of HKD 2,690,000 in the previous year[4] - The net loss attributable to the company’s owners for the period was HKD 1,587,000, a reversal from a profit of HKD 1,693,000 in 2023[4] - The basic and diluted loss per share for the period was HKD 0.09, compared to earnings of HKD 0.11 per share in the same period last year[4] - The overall gross profit margin for the company was 2.71%, down from 14.41% in the previous year[46] - The company recorded a loss of approximately HKD 1,590,000 for the six months ended September 30, 2024, compared to a profit of HKD 960,000 for the same period in 2023[47] - Total loss before tax for the group was HKD (1,553,000), with a net loss of HKD (1,588,000) for the six months ended September 30, 2024[17] Assets and Liabilities - The total assets as of September 30, 2024, were HKD 331,647,000, slightly up from HKD 330,707,000 as of March 31, 2024[6] - Current liabilities amounted to HKD 68,840,000, with cash and cash equivalents at approximately HKD 179,000, indicating potential liquidity issues[11] - The company had trade payables of HKD 28,775,000 as of September 30, 2024, slightly up from HKD 28,380,000 as of March 31, 2024[37] - Trade receivables amounted to HKD 96,230,000 as of September 30, 2024, an increase from HKD 73,560,000 as of March 31, 2024[34] - The company’s equity attributable to owners was HKD 269,500,000, a slight decrease from HKD 269,847,000 as of March 31, 2024[6] - The capital debt ratio as of September 30, 2024, was approximately 0.94%, unchanged from March 31, 2024[56] Revenue Segmentation - The group reported a total revenue of HKD 37,186,000 for the health products and services business, with a segment loss of HKD (80,000) for the six months ended September 30, 2024[17] - The liquor sales business generated revenue of HKD 37,186,000, resulting in a segment loss of HKD (410,000) for the same period[17] - The health products and services segment did not generate any revenue during the reporting period, compared to HKD 41,270,000 in the previous year, resulting in a segment loss of HKD 80,000[48] - The liquor sales segment generated revenue of HKD 37,190,000 for the six months ending September 30, 2024, with a segment loss of HKD 410,000[51] - The group’s revenue from external customers in China was HKD 37,186,000, down from HKD 42,125,000 in the previous period[19] Cash Flow and Financing - The company has taken measures to accelerate the collection of outstanding trade receivables to improve cash flow[11] - The group has implemented cost control measures to enhance profitability and improve future cash flow[12] - The group plans to actively seek new financing arrangements to meet operational and financial needs[12] - The group had cash and bank balances of approximately HKD 200,000 as of September 30, 2024, down from approximately HKD 500,000 as of March 31, 2024[56] Corporate Governance - The board consists of four executive directors and four independent non-executive directors, and the financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards[54] - The board of directors includes Chairman and CEO Wang Mengyao, and other executive and independent non-executive directors[73] Other Information - The group did not declare any dividends for the current interim period[30] - The company did not recommend an interim dividend for the six months ending September 30, 2024, consistent with the previous year[67] - The group has not engaged in any significant acquisitions or disposals of subsidiaries or associates during the reporting period[61] - The company has not pledged any assets as of September 30, 2024[62] - The group has no significant contingent liabilities as of September 30, 2024[63] - The company allowed credit terms ranging from 0 to 365 days for health products and services and liquor sales[34] - The group has adopted new and revised Hong Kong Financial Reporting Standards effective from April 1, 2024, with no significant impact on accounting policies or financial statements[13] - The lending business recorded no revenue for the six months ending September 30, 2024, compared to HKD 30,000 for the same period last year, maintaining a gross profit margin of 100% due to no financial costs[50] - The company has exclusive rights to sell "Emperor Pool" liquor in China, which is expected to enhance financial performance and profitability due to the growing demand for liquor driven by rising living standards[51] - The announcement date is November 29, 2024, indicating a recent financial update[73]
莲和医疗(00928) - 2025 - 中期业绩